156 related articles for article (PubMed ID: 32231544)
1. Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy.
Yamaguchi T; Masumoto M; Sakurai U; Nakane M
Case Rep Oncol; 2020; 13(1):193-199. PubMed ID: 32231544
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients.
Shinden Y; Sugimachi K; Tanaka F; Fujiyoshi K; Kijima Y; Natsugoe S; Mimori K
Mol Clin Oncol; 2018 Jan; 8(1):93-98. PubMed ID: 29423222
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
4. Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer.
Ota T; Miyatake N; Tanaka N; Hasegawa Y; Tokunaga M; Tsukuda H; Fukuoka M
Gynecol Endocrinol; 2018 Apr; 34(4):286-289. PubMed ID: 29069999
[TBL] [Abstract][Full Text] [Related]
5. [Bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation in a Breast Cancer Patient Treated with Chemotherapy and CDK4/6 Inhibitor].
Kume S; Makino T; Goto A; Onodera Y; Kudo S
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1331-1333. PubMed ID: 38247075
[TBL] [Abstract][Full Text] [Related]
6. A case of disseminated carcinomatosis of the bone marrow from gastric cancer developing rapidly after a gastrectomy.
Sato S; Ishibashi Y; Kawasaki K; Yamazaki R; Hatao F; Morita Y; Imamura K
Surg Case Rep; 2021 Feb; 7(1):49. PubMed ID: 33591417
[TBL] [Abstract][Full Text] [Related]
7. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Bone Marrow Carcinomatosis of Occult Breast Cancer Treated Effectively with Fulvestrant].
Tomida S; Nakatsukasa K; Taguchi T
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1381-1384. PubMed ID: 30237387
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
10. Disseminated carcinomatosis of the bone marrow from pancreatic cancer: a case report.
Namikawa H; Takemoto Y; Makuuchi A; Kobayashi M; Kinuhata S; Morimura M; Ikebe T; Tanaka H; Shuto T
BMC Cancer; 2016 Oct; 16(1):801. PubMed ID: 27769217
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
Reinert T; Barrios CH
Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
13. Bone Marrow Carcinomatosis in a Stage IV Breast Cancer Patient Treated by Letrozole as First-Line Endocrine Therapy.
Nakagawa T; Hayashi K; Ogawa A; Oda G; Onishi I; Yamamoto M; Mori M; Fujioka T; Ishikawa T; Okamoto K; Uetake H
Case Rep Oncol; 2022; 15(1):436-441. PubMed ID: 35702555
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
15. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. [Bone Marrow Metastases of Breast Cancer Treated with Endocrine Therapy-A Case Report].
Okamoto A; Saito A; Konishi M; Shimada N; Matsuo Y; Sugitani Y; Soyama M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2583-2585. PubMed ID: 32157006
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
19. Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.
Porter K; Rosenzweig MQ
J Adv Pract Oncol; 2017 Mar; 8(2):164-168. PubMed ID: 29900024
[No Abstract] [Full Text] [Related]
20. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
